Tonix announces successful end-of-phase 2 meeting with FDA for TNX-102 SL in PTSD
Tonix Pharmaceuticals, which is developing next-generation medicines for fibromyalgia and post-traumatic stress disorder (PTSD), has received the final meeting minutes from the U.S. Food and Drug Administration (FDA) from an End-of-Phase 2/Pre-Phase 3 meeting.
Click on this link for more information.
